2008年7月
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- ,
- ,
- ,
- ,
- 巻
- 111
- 号
- 1-2
- 開始ページ
- 13
- 終了ページ
- 17
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.jsbmb.2008.04.004
- 出版者・発行元
- PERGAMON-ELSEVIER SCIENCE LTD
Objectives: To evaluate the efficacy and safety of combing aromatase inhibitor (AI) and cyclooxygenase-2 (COX-2) inhibitor neoadjuvantly in postmenopausal patients with invasive hormone-sensitive breast cancer.
Methods: Eighty-two patients were randomly assigned to receive exemestane 25 mg daily and celecoxib 400 mg twice daily (group A, n = 30), exemestane 25 mg daily (group B, n = 24) and letrozole 2.5 mg daily (group C, n = 28).
Results: All groups showed clinical responses (58.6% for group A, 54.5% for group B and 62.0% for group C) and decrease in tumor area (61.8% for group A, 58.1% for group B and 55.7% for group Q. 3 out of 5 patients with complete clinical response were observed from group A and 2 out of 69 patients operated with pathologic complete response were observed in group C. The mean microscopic tumor size was 2.53 cm for group A, 3.05 cm for group B and 2.10 cm for group C. The differences were only statistically significant when group C was compared with group B (P = 0.025). The toxicity profiles among groups were satisfactory.
Conclusion: AI is effective in treating breast cancer and may be safely used preoperatively. The addition of COX-2 inhibitor may provide additional benefit. (C) 2008 Elsevier Ltd. All rights reserved.
Methods: Eighty-two patients were randomly assigned to receive exemestane 25 mg daily and celecoxib 400 mg twice daily (group A, n = 30), exemestane 25 mg daily (group B, n = 24) and letrozole 2.5 mg daily (group C, n = 28).
Results: All groups showed clinical responses (58.6% for group A, 54.5% for group B and 62.0% for group C) and decrease in tumor area (61.8% for group A, 58.1% for group B and 55.7% for group Q. 3 out of 5 patients with complete clinical response were observed from group A and 2 out of 69 patients operated with pathologic complete response were observed in group C. The mean microscopic tumor size was 2.53 cm for group A, 3.05 cm for group B and 2.10 cm for group C. The differences were only statistically significant when group C was compared with group B (P = 0.025). The toxicity profiles among groups were satisfactory.
Conclusion: AI is effective in treating breast cancer and may be safely used preoperatively. The addition of COX-2 inhibitor may provide additional benefit. (C) 2008 Elsevier Ltd. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.jsbmb.2008.04.004
- ISSN : 0960-0760
- Web of Science ID : WOS:000258790800003